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Abstract
Objective: To present an update on incidence and mortality from adverse effects (AEs) of medical
treatment in the UK, its four countries and nine English regions between 1990 and 2013.
Design: Descriptive epidemiological study on AEs of medical treatment. AEs are shown as a single
cause-of-injury category from the Global Burden of Disease (GBD) 2013 study.
Data sources: The GBD 2013 interactive data visualisation tools ‘Epi Visualisation’ and ‘GBD Compare’.
Outcome measures: The means of incidence and mortality rates with 95% uncertainty intervals
(UIs). The estimates are age-standardised.
Results: Incidence rate was 175 and 176 cases per 100 000 men, 173 and 174 cases per 100 000
women in 1990 and 2013, in the UK (UI 170–180). The mortality from AEs declined from 1.33 deaths
(UI 0.99–1.5) to 0.92 deaths (UI 0.75–1.2) per 100 000 individuals in the UK between 1990 and 2013
(30.8% change). Although mortality trends were descending in every region of the UK, they varied
by geography and gender. Mortality rates in Scotland, North East England and West Midlands
were highest. Mortality rates in South England and Northern Ireland were lowest. In 2013, age-
speciﬁc mortality rates were higher in males in all 20 age groups compared with females.
Conclusions: Despite gains in reducing mortality from AEs of medical treatment in the UK
between 1990 and 2013, the incidence of AEs remained the same. The results of this analysis sug-
gest revising healthcare policies and programmes aimed to reduce incidence of AEs in the UK.
Key words: adverse events, patient safety, patient outcomes (health status, quality of life, mortality), measurement of quality,
mortality, complications, quality culture, quality management, health policy, healthcare system
Introduction
Comprehensive scans of research on harm related to adverse effects
(AEs) arising from medical treatment in the UK show that knowl-
edge on occurrence of AEs in the UK is based on the reviews of ran-
domly drawn medical and nursing records from selected acute-care
hospitals in UK at ﬁxed time points [1, 2]. It is commonly stated
that 8–12% of patients—or ~1 in 10 patients—admitted to a large
acute-care hospital in UK experience an AE from medical treatment;
a third of them usually lead to moderate or severe disability or death
[3–5]. However, little is known about the levels, trends, and patterns
in incidence and mortality rates from hospital setting AEs in the UK
and its regions over time.
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The Global Burden of Disease (GBD), injuries and risk factors
study led by Murray [6, 7] provides a standardised approach to
addressing this problem. Its interactive data visualisation system is a
publicly available platform to retrieve, interpret and compare the
standardised epidemiological estimates for AEs from medical treat-
ment at the population level of individual countries and their regions
by age, gender, geography and year [8, 9].
In this article built on the GBD 2013 study, we show the inci-
dence and mortality of AEs resulting from medical treatment in the
UK, its four constituent countries and nine regions of England [10]
over a period of 24 years, 1990–2013. We show levels of, trends for
and patterns from AEs resulting from medical treatment in the UK.
The comparisons of AE incidence and death rates are provided for
understanding the ranking of the UK on the scale of 33 highly indus-
trialised high-income countries. It is important to note that AEs
related to medical treatment in this article are deﬁned as a single
cause-of-injury category—an aggregate of 311 individual AEs result-
ing from medical treatment.
Methods
GBD study deﬁnition
The GBD study is a systematic, scientiﬁc enterprise to measure epi-
demiological levels of and quantify the magnitude of health loss from
diseases, injuries and risk factors by age, gender and geography for spe-
ciﬁc points in time [6]. The GBD 2013 is a systematic, comprehensive
effort to quantify health loss from 306 causes of diseases, 240 causes
of death and 79 risk factors by gender and age groups between 1990
and 2013 for 188 countries. Detailed descriptions of the methodology
of the GBD 2013 study are provided elsewhere [7, 11, 12].
Adverse effects
An AE from medical treatment is a documented and coded injury
resulting from a patient’s medical management. Only AEs of medical
treatment at emergency departments and other hospital units were
included into the process of estimations. A detailed list of the
International Classiﬁcation of Diseases, Ninth Revision, and the
International Statistical Classiﬁcation of Diseases and Related Health
Problems, Tenth Revision, codes for AEs of medical treatment and
other supplemental information on the burden of injury from AEs of
medical treatment are available in the annex of Global Burden of
Injury paper [12]. The terms ‘AEs from medical treatment’, ‘clinical
AEs’, ‘adverse effects arising from medical treatment’ and ‘adverse
effects resulting from medical treatment’ are synonymous in this paper.
Data sources
For this analysis, we retrieved the age-standardised incidence and
mortality means with 95% uncertainty intervals (UIs) for AEs of med-
ical treatment from GBD 2013 interactive data visualisation tools ‘Epi
Visualisation’ and ‘GBD Compare’ [8, 9]. The incidence and mortality
estimates are age-standardised using the revised GBD 2013 standard
population [7]. The UI expresses measurement error affecting data
inputs. It is presented by the 2.5 and 97.5 centile values. Selection of
the model—AEs of medical treatment—within the data visualisation
tool allowed extraction of the pre-adjusted and post-adjusted AE inci-
dence and mortality epidemiological estimates for every region of
England, every constituent country of the UK, and every individual
highly industrialised high-income country, by age, gender, geography
and year. We used ﬁnal ﬁts for the years 1990, 1995, 2000, 2005,
2010 and 2013 for this study. Model results retrieved from both
interactive data visualisation tools were entered into standard
Microsoft® Excel Mac2011 spreadsheets. Subsequently, these results
were further analysed using functions of this programme and bearing
in mind the conception and aims of this study.
Incidence
The incident case is deﬁned as a newly diagnosed case with the AE
resulting from medical treatment in a population in a given period—a
year. Incidence expressed as a rate is deﬁned as the number of new cases
per person a year. It is approximately measured by taking the number
of new cases in a year divided by the mid-year population of a country
or region. Example: incidence at the level 0.0017558861581211 for
one male individual in 2013 means that incidence of the particular
condition is 176 new cases per 100 000 men in 2013. To estimate
incidence rates with 95% UIs by age, gender, geography and year, a
descriptive epidemiological meta-regression tool DisMod-MR 2.0
was applied. Information on estimated population size for the coun-
tries of the UK and the English regions in mid-1990 and mid-2013
was provided by Ofﬁce for National Statistics, National Records of
Scotland, Northern Ireland Statistics and Research Agency for the
calculations of incident cases in men and women in 1990 and
2013 [13].
Mortality
Mortality expressed as a rate is deﬁned as the number of deaths due to
AEs resulting from medical treatment per person a year among the
entire population. For instance, the mortality rate from AEs from med-
ical treatment 0.000012 for the UK’s men in 1990 means that there
were 1.2 deaths per 100 000 or 12 deaths per 1 million men due to AEs
resulting from medical treatment in the UK in 1990. To derive mortality
rates with 95% UIs by age, gender, geography and year, the GBD cause
of death ensemble modelling (CODEm) software was used.
Percentage change and difference
The percentage change between two mean values represents the degree
of change—percent increase, percent decrease or decline—at different
points in time, i.e. between 1990 and 2013 in this paper. The percent-
age difference between two mean values was calculated to show a dis-
tribution of the differences between AE age-speciﬁc mortality rates in
men and women of the UK in 2013, i.e. at the same time point.
High-income countries
The set of 33 high-income countries includes four high-income Asia
Paciﬁc countries (Brunei, Japan, Singapore and South Korea), two
Australasia countries (Australia and New Zealand), two North
America countries (Canada and USA), three South American coun-
tries (Argentina, Chile and Uruguay) and 22 Western Europe coun-
tries (Andorra, Austria, Belgium, Cyprus, Denmark, Finland, France,
Germany, Greece, Iceland, Ireland, Italy, Israel, Luxembourg, Malta,
the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and
the UK). The UK was compared with 32 other high-income countries
to provide the meaningful comparisons of the rates of incidence and
mortality from AEs of medical treatment.
Results
Incidence
Estimates of incident cases with 95% UIs from AEs arising from
medical treatment in the UK in 1990 and 2013 is presented in
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Table 1. In 1990 and 2013, the age-standardised incidence rate was
175 and 176 per 100 000 men, 173 and 174 per 100 000 women in
the UK (95% UI 170–180). Figure 1 demonstrates stability in inci-
dence from clinical AEs among men and women in the geographical
regions of the UK between 1990 and 2013.
Figure 2 shows age-standardised incidence rates with 95% UIs
from 33 high-income countries in 2013, by gender. It illustrates a
similar incidence rate among men and women in 30 countries out of
33. The USA, Canada and the Netherlands stand out with age-
standardised incidence rates of 400, 280 and 250 cases per 100 000
men, and 390, 270 and 250 cases per 100 000 women in 2013,
respectively. Comparison of age-standardised incidence rates of AE
of 33 high-income countries over time shows that the age-standardised
incidence rates of AEs resulting from medical treatment remained
stable over time between 1990 and 2013 for both genders.
Incidence by age and gender
Figure 3 shows the trends of age-speciﬁc incidence rates of AEs resulting
from medical treatment in men and women in the UK in 1990 and
2013. All trend lines are gradually ascending from the age group
10–14. Trends are more distinct for men. The biggest difference in age-
speciﬁc incidence rates among men and women observed is in the age
group 75–79. The incidence rate in the 75–79 age groups was higher in
men by 12.3% in 1990 and by 15.1% in 2013. The ﬁgure suggests a
division of each trend line into four portions reﬂecting age groups
0–364 days (moderately high incidence rates), 1–9 years (lowest rates),
10–64 years (steadily increasing rates) and 65–80+ years (extremely
high incidence rates). It reﬂects greater morbidity related to clinical AEs
in neonates and elderly.
Mortality
Table 2 provides information on a number of deaths and age-
standardised mortality rates (ASMR) with 95% UIs from AEs resulting
from medical treatment in individuals of both genders combined in
1990 and 2013, within the regional geography of England and a con-
stituent country of the UK. The ASMR from AEs resulting from med-
ical treatment declined from 1.33 deaths (95% UI 0.99–1.5) to 0.92
deaths (95% UI 0.75–1.2) per 100 000 individuals in the UK between
1990 and 2013 (30.8% change). The number of deaths decreased by
8.6% in the UK. The positive change in Greater London is notable—
27.8% decrease in deaths and 37% change in ASMR from 1990 and
2013. In contrast, the number of deaths increased in Northern Ireland
and Scotland by 13.5%. The decrease of ASMR in Scotland was the
least within the geographical regions of the UK—13.7%.
As shown in Fig. 4, ASMR trends were descending in every
region of the UK from 1990 to 2013. However, the ASMRs varied
by geography and gender. ASMRs in Scotland, North East England
and West Midlands were highest, whereas ASMRs in Northern
Ireland and both regions of South England were lowest. Overall,
progress in all regions of England and Wales was achieved.
Figure 5 shows notable variations in ASMRs fromAEs of medical treat-
ment in 2013, by high-income country. Comparison of ASMRs among
women showed that the UK was performing worse than Switzerland by
9.9 times, Singapore by 4.5 times, Finland by 3.5 times, Norway by 3.1
times, Brunei by 2.8 times and Malta by 2.1 times in 2013. In men, the
UK was performing worse than Switzerland by 10.1 times, Singapore
by 5.1 times, Finland by 4.2 times and Norway by 2.7 times.
Mortality by age and gender
Figure 6 depicts a pattern of age-speciﬁc mortality rates from AEs
resulting from medical treatment among men and women in the UK. It
shows that age-speciﬁc mortality rates are comparable in newborn
Table 1 Incident cases with 95% uncertainty intervals of adverse effects resulting from medical treatment in the UK in 1990 and 2013, by
gender and geographical region
Men Women
1990 2013 1990 2013
East of England 4363 (3993–4742) 5140 (4687–5566) 4489 (4148–4925) 5307 (4840–5747)
East Midlands 3422 (3136–3724) 3953 (3629–4309) 3538 (3253–3863) 4054 (3729–4428)
Greater London 5813 (5252–6236) 7401 (6665–7914) 6088 (5626–6681) 7346 (6802–8077)
North East 2183 (2004–2380) 2261 (2046–2429) 2293 (5641–6698) 2295 (2131–2531)
North West 5725 (5286–6278) 6119 (5592–6641) 6035 (5641–6698) 6285 (5773–6856)
South East 6404 (5925–7036) 7456 (6918–8215) 6839 (6232–7400) 7751 (7150–8491)
South West 3978 (3619–4297) 4674 (4225–5017) 4134 (3850–4572) 4766 (4380–5201)
West Midlands 4517 (4096–4864) 4926 (4486–5327) 4660 (4253–5051) 5030 (4593–5455)
Yorkshire and the Humber 4195 (3827–4545) 4633 (4208–4997) 4358 (4046–4805) 4685 (4332–5145)
Northern Ireland 1368 (1245–1478) 1590 (1435–1705) 1412 (1308–1554) 1627 (1492–1772)
Scotland 4279 (3910–4643) 4553 (4138–4914) 4585 (4220–5011) 4856 (4386–5208)
Wales 2442 (2215–2631) 2655 (2424–2879) 2573 (2363–2806) 2733 (2507–2978)
UK 48 690 (47 292–50 073) 55 368 (53 606–56 759) 51 006 (50 012–52 954) 56 671 (55 374–58 631)
Figure 1 Trend line chart from the mean age-standardised incidence rates
per 100 000 individuals with adverse effects resulting from medical treatment
in the UK, by geography, gender and year.
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infants and in 70–74-year-old individuals. All four trend lines for age-
speciﬁc mortality begin to markedly increase in the age group of 60–64
years. The highest age-speciﬁc mortality rates were in the age group
≥80 with 130 deaths per 1 million men and 120 deaths per 1 million
women in 2013.
In 1990, nearly all age-speciﬁc mortality rates—age groups from 10
to 24 years were the exceptions—were higher among women. In con-
trast, they were universally higher among men in all 20 age groups in
2013 in the UK. Figure 7 highlights the distribution of percentage differ-
ences between AE age-speciﬁc mortality rates in men and women in the
UK in 2013. The greatest difference in age-speciﬁc mortality rates was
observed in the age groups 20–24 and 25–29, 30.1% and 26.7%,
respectively. The descending trend line shows that a factor of male gen-
der for mortality from AEs arising from medical treatment is diminish-
ing in the population of older individuals.
Discussion
The key epidemiological estimates for AEs of medical treatment
across age, gender, time and place have recently been publicised at
the global level [7, 11, 14]. In the current study, we aimed to pro-
vide a description of levels, trends, and patterns of incidence and
mortality from AEs of medical treatment in the countries of the UK
and the regions of England from 1990 to 2013. The comparisons of
AE incidence and death rates for the high-income countries are pro-
vided in this study to pinpoint ranking of the UK on the scale of 33
industrialised countries.
This paper shows that reduction in incidence and mortality from
AEs resulting from medical treatment is a challenging task for every
high-income country. The decline in ASMR from 1990 to 2013 indi-
cates the progress in the UK in improving clinical outcomes related
to AEs arising from medical treatment. However, age-standardised
incidence rates did not change markedly in the UK between 1990
and 2013. They varied only minimally by region and gender.
Interestingly, the levels of age-standardised incidence rates were
similar in the majority of high-income countries.
Despite the reduction of ASMR from AEs resulting from medical
treatment by 30.8% in the UK from 1990 and 2013, ASMRs varied
visibly by the regional geography of the state. It is important to rec-
ognise that disparities persisted between North England and South
England, Scotland and England, East Midlands and West Midlands.
This analysis shows the lowest ASMRs in Northern Ireland and the
highest ASMRs in Scotland. This phenomenon, therefore, has to be
further discussed in editorials and national forums [15], for inequal-
ities in mortality rates in the regions of the UK—where healthcare
service is universal, comprehensive and equitable, and where there is
nearly identical incidence—should not be tolerated. It is very likely
that it may be related to a not-proportionate healthcare spending
within the UK [16].
Comparison of age-speciﬁc mortality rates by gender revealed
higher rates in all 20 age groups of men in 2013, with the highest
age-speciﬁc mortality rates in newborn infants and 70–74-year-old
men and women. This indicates that gender may be an important
factor in mortality from clinical AEs.
The number of deaths from AEs resulting from medical treat-
ment was stagnant in the UK between 1990 and 2013, ~1000 a
year, as declining ASMRs did not outpace the increase in population
of the UK. Such patterns suggest that death levels will not change in
Figure 2 Similar age-standardised incidence rates with 95% uncertainty intervals for adverse effects resulting from medical treatment in 33 high-income coun-
tries in 2013, by gender.
Figure 3 Trends from age-speciﬁc incidence rates for adverse effects resulting
from medical treatment per 100 000 individuals in 1990 and 2013, by gender, UK.
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the UK if additional or entirely new strategies and measures for pre-
vention of clinical AEs in the UK are not designed and implemented.
Besides the strengths of this paper, a few limitations have to be men-
tioned. First, the actual age-standardised incidence and mortality due to
AEs resulting from medical treatment can differ from the GBD 2013
study estimates as culture of under-reporting and not-coding of clinical
AEs prevails in healthcare facilities of the UK [17, 18]. Furthermore, the
correct estimation of mortality from AEs resulting from medical treat-
ment is even more hindered by the unavoidable overlap of the natural
cause of the underlying illness itself and a clinical AE. Second, the deﬁn-
ition of AEs resulting from medical treatment and the selection of codes
for these could be questioned and challenged, as more ICD-10 codes
may have been taken into account when estimating the burden of
AEs resulting from medical treatment. The third limitation of this
study is related to a bias occurring from mismanagement of the
patients due to problems related to inadequate infrastructure
resources, medical understafﬁng and ineffective communication that
may often result in delays of timely treatment [19, 20]. Such clinical
events are regarded as clinical incidents, for they do have clinical con-
sequences to the patients and to the entire medical care system [21].
However, they are usually not coded as AEs resulting from medical
treatment and, therefore, not reported to national registration systems
in the form of ICD codes.
This review may have several educational and practical implica-
tions. As progress has not been made to achieve a reduction in the
age-standardised incidence rate of AEs resulting from medical treat-
ment across the UK between 1990 and 2013, it challenges the efﬁ-
cacy and effectiveness of the clinical risk management programmes
and tools aimed to improve inpatient and outpatient safety and
reduce the incidence of AEs resulting from medical treatment [22].
Therefore, new or newly revisited interventions to improve the pro-
cess of mandatory, systematic and daily registration and coding of
all AEs resulting from medical treatment would be beneﬁcial for the
healthcare system. Without precise daily capture and registration of
clinical AEs of all categories of severity, and without regular epi-
demiological analysis and assessment of clinical AEs, a reduction of
incidence and, subsequently, the burden of AEs resulting from med-
ical treatment may be hardly achievable. Furthermore, as Buist and
Middleton have recently suggested, entirely new concepts to better
understand and manage more complex hospital setting AEs with the
aim of designing interventions that are more focused on a hospital’s
core business are needed [23, 24].
This study also implies that additional efforts are necessary to
make the medical interventions safer for two marginal age groups of
individuals—neonatal and elderly—in order to meet the demand
generated by the growing number of the populations from these age
groups in the UK [25, 26]. Finally, comparisons of ASMR within
the set of 33 high-income countries and the modest (the 15th) rank-
ing of the UK suggest that it is time to reconsider key points con-
cerning the interaction between the patient and the healthcare
professional [24].
Table 2 Deaths and age-standardised mortality rates (ASMR) with 95% UIs and percentage change from adverse effects resulting from
medical treatment in men and women combined in the UK in 1990 and 2013, by regional geography
Deaths in 1990 Deaths in 2013 Percentage
change
ASMR per
100 000 in 1990
ASMR per
100 000 in 2013
Percentage
change
East of England 93.33 (64.4–112.2) 90.95 (69.15–133.58) −2.6 1.26 (0.88–1.5) 0.82 (0.63–1.17) −34.9
East Midlands 74.93 (54.19–92.79) 71.74 (54.59–103.59) −4.3 1.33 (0.96–1.62) 0.89 (0.69–1.25) −33.1
Greater London 124.51 (87.64–147.68) 89.91 (65.53–127.27) −27.8 1.35 (0.96–1.58) 0.85 (0.65–1.25) −37.0
North East 55.49 (39.75–67.27) 48.75 (36.55–70.6) −12.1 1.55 (1.12–1.88) 1.05 (0.8–1.49) −32.3
North West 135.44 (92.27–162.13) 108.48 (82.56–151.96) −19.9 1.38 (0.97–1.63) 0.9 (0.7–1.25) −34.8
South East 127.41 (86.63–151.06) 116.08 (86.99–166.58) −8.9 1.08 (0.76–1.27) 0.72 (0.54–1.01) −33.3
South West 79.91 (54.13–96.07) 75.44 (57.52–104.17) −5.6 1 (0.69–1.18) 0.68 (0.53–0.93) −32.0
West Midlands 105.9 (75.16–128.16) 100.56 (75.99–136.71) −5.0 1.49 (1.07–1.8) 1.03 (0.79–1.41) −30.9
Yorkshire and the Humber 93.78 (64.17–112.18) 77.47 (60.92–116.4) −17.4 1.32 (0.92–1.56) 0.86 (0.68–1.26) −34.9
England 890.7 (644.41–999.76) 776.39 (645.07–1045.15) −12.7 1.28 (0.94–1.44) 0.85 (0.7–1.14) −33.6
Northern Ireland 15.92 (12.31–20.04) 18.4 (14.18–24.46) 13.5 0.84 (0.65–1.05) 0.68 (0.53–0.91) −19.1
Scotland 137.94 (108.35–174.1) 159.49 (105.54–194.22) 13.5 1.99 (1.56–2.48) 1.73 (1.18–2.1) −13.7
Wales 53.61 (37.64–64.25) 49.46 (37.28–69.95) −7.7 1.24 (0.88–1.47) 0.87 (0.68–1.19) −29.8
UK 1098.17 (805.99–1236.6) 1003.75 (815.75–1302.58) −8.6 1.33 (0.99–1.5) 0.92 (0.75–1.2) −30.8
UI, uncertainty interval (estimates in brackets); ASMR, age-standardised mortality rate per 100 000 individuals. Estimates for years 1990, 1995, 2000, 2005,
2010 and 2013 are available at http://vizhub.healthdata.org/gbd-compare.
Figure 4 Variations in age-standardised mortality rates per 1 000 000 indivi-
duals from adverse effects resulting from medical treatment, by regional
geography of the UK, gender and year; data sorted in descending order for
men for the year 1990.
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Conclusions
Progress has not been achieved in the reduction of incidence of AEs
arising from medical care in the UK. AE incidence rate was essen-
tially stable between 1990 and 2013. Age-speciﬁc incidence rates
were highest in neonates and elderly. Although mortality rate trends
are descending in every region of the UK, they varied by the regional
geography, gender and age group. Mortality rates were higher
among UK’s men in all 20 age groups in 2013. The UK is perform-
ing worse than Switzerland by ten times regarding mortality rates.
Although synthesis of accurate identiﬁcation, immediate electronic
registration, meticulous coding of an AE resulting from medical
treatment and regular analysis is a useful tool to learn lessons and
reduce the occurrence and burden from clinical AEs, new strategies
and policies that put the patient ﬁrst are needed. In essence, it is all
about the new shift in quality culture in healthcare organisation and
provision in the UK.
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